menu
    • menu
    [{"orgOrder":0,"company":"Nested Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"NEST-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nested Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nested Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Nested Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Nested Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NST-628","moa":"Pan-RAF\/MEK","graph1":"Oncology","graph2":"Phase I","graph3":"Nested Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nested Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nested Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nested Therapeutics

    Menu

    Nested Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nested Therapeutics

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed

                            Nested Therapeutics

                            U.S.A arrow
                            BioTrinity 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NST-628

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nested Therapeutics FDA Clearance for NST-628, a Pan-RAF/MEK Molecular Glue

                            Details : NST-628 is a novel pan-RAF/MEK molecular glue targeting the RAS-MAPK pathway, evaluated for RAS-MAPK mutated advanced solid tumors.

                            Product Name : NST-628

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2024

                            Lead Product(s) : NST-628

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nested Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Nested Therapeutics

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEST-1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Versant Ventures

                            Deal Size : $125.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Nested Therapeutics Launches With $125 Million Financing

                            Details : The financing will enable Nested to advance its pipeline including NEST-1, and further develop its platform that reveals cryptic, or newly uncovered, driver mutations and pockets in high-conviction cancer targets to dramatically expand the reach of preci...

                            Product Name : NEST-1

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 10, 2022

                            Lead Product(s) : NEST-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Versant Ventures

                            Deal Size : $125.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth